# US 2023/0272391 A1 · Adar dependent editing compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272391 A1
- Document ID: US20230272391A1
- Status: Published application
- Kind: A1
- Application number: 18/018,379
- Filed: 2021-07-30
- Published: 2023-08-31
- Earliest claimed: 2020-07-30
- Assignees: ADARx Pharmaceutical, Inc.
- Applicants: ADARx Pharmaceutical, Inc.
- Inventors: Zhen Li; Rui Zhu; Jean da Silva Correia; Kimberly Fultz; Sean Studer; Sam Lear
- Web page: https://patentgrep.com/patent/US20230272391A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/85: for animal cells
- C12Y 102/01012: Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein are compositions and methods for recruiting and using ADAR. In some aspects, compositions and methods for targeting ADAR activity to a desired region, sequence, or nucleotide are disclosed. In some aspects, compositions and methods for increasing the efficiency of directed ADAR editing are disclosed.

## Claims

### Claim 1

An adenosine deaminase acting on ribonucleic acid (RNA) (ADAR) recruiting molecule comprising a double-stranded RNA duplex, wherein the double-stranded RNA duplex comprises two strands of RNA of an equal number of nucleotides, which two RNA strands are not connected to one another by means of a hairpin, wherein:
(a) the 5′ nucleotide of each RNA strand is complementary to the 3′ nucleotide of the other RNA strand;
(b) at least one RNA strand of the double-stranded RNA duplex comprises at least one nucleoside modification and/or at least one backbone modification; and
(c) the double-stranded RNA duplex comprises at least one base pair mismatch, wherein the mismatch is not positioned at either terminal nucleotide base pair of the double-stranded RNA duplex.

### Claim 2 (depends on 1)

The ADAR recruiting molecule of claim 1, further comprising a single-stranded guide nucleic acid.

### Claim 3 (depends on 1, 2)

The ADAR recruiting molecule of claim 1 or claim 2, wherein the double-stranded RNA duplex comprises at least one nucleoside modification and at least one backbone modification.

### Claim 4 (depends on 1, 2, 3)

The ADAR recruiting molecule of any one of claims 1-3, wherein the at least one nucleoside modification of the double-stranded RNA duplex comprises a 2′-aminoethyl, a 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid, a 2′-O-methyl, a 2′-O-methoxyethyl (2′O-MOE), or a 2′-fluoro modification.

### Claim 5 (depends on 1, 2, 3, 4)

The ADAR recruiting molecule of any one of claims 1-4, wherein the at least one backbone modification of the double-stranded RNA duplex comprises a phosphorothioate modification.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The ADAR recruiting molecule of any one of claims 1-5, wherein the at least one backbone modification of the double-stranded RNA duplex is positioned within 1-5 nucleotides of the terminal nucleotide of the RNA strand on which it is located.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The ADAR recruiting molecule of any one of claims 1-6, wherein the at least one backbone modification of the double-stranded RNA duplex is positioned within 1-3 nucleotides of the terminal nucleotide of the RNA strand on which it is located.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The ADAR recruiting molecule of any one of claims 1-7, wherein the at least one backbone modification of the double-stranded RNA duplex is positioned within 1 nucleotide of the terminal nucleotide of the RNA strand on which it is located.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The ADAR recruiting molecule of any one of claims 1-8, wherein the double-stranded RNA duplex comprises more than one nucleoside modification.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The ADAR recruiting molecule of any one of claims 1-9, wherein the double-stranded RNA duplex comprises more than two nucleoside modifications.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The ADAR recruiting molecule of any one of claims 1-10, wherein more than 25% of the nucleosides in the double-stranded RNA duplex comprise a nucleoside modification.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The ADAR recruiting molecule of any one of claims 1-11, wherein more than 50% of the nucleosides in the double-stranded RNA duplex comprise a nucleoside modification.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The ADAR recruiting molecule of any one of claims 1-12, wherein more than 75% of the nucleosides in the double-stranded RNA duplex comprise a nucleoside modification.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The ADAR recruiting molecule of any one of claims 1-13, wherein the double-stranded RNA duplex comprises more than one backbone modification.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The ADAR recruiting molecule of any one of claims 1-14, wherein the double-stranded RNA duplex comprises more than two backbone modifications.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The ADAR recruiting molecule of any one of claims 1-15, wherein the double-stranded RNA duplex comprises more than three backbone modifications.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The ADAR recruiting molecule of any one of claims 1-16, wherein more than 25% of the internucleoside linkages of the double-stranded RNA duplex comprise a modification.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The ADAR recruiting molecule of any one of claims 1-17, wherein more than 50% of the internucleoside linkages of the double-stranded RNA duplex comprise a modification.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The ADAR recruiting molecule of any one of claims 1-18, wherein more than 75% of the internucleoside linkages of the double-stranded RNA duplex comprise a modification.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The ADAR recruiting molecule of any one of claims 1-19, further comprising nucleotides attached to the 3′ end or 5′ end of at least one of the RNA strands of the double-stranded RNA duplex creating a 3′ or 5′ end overhang.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The ADAR recruiting molecule of any one of claims 1-20, further comprising an additional moiety.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The ADAR recruiting molecule of any one of claims 1-21, further comprising a linker.

### Claim 23 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The ADAR recruiting molecule of any one of claims 2-22, wherein the single-stranded guide nucleic acid is guide Ribonucleic Acid (gRNA).

### Claim 24 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The ADAR recruiting molecule of any one of claims 2-23, wherein the single-stranded guide nucleic acid comprises at least one nucleoside modification.

### Claim 25 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The ADAR recruiting molecule of any one of claims 2-23, wherein the single-stranded guide nucleic acid comprises at least one backbone modification.

### Claim 26 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The ADAR recruiting molecule of any one of claims 2-25, wherein the single-stranded guide nucleic acid comprises at least one nucleoside modification and at least one backbone modification.

### Claim 27 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The ADAR recruiting molecule of any one of claims 2-26, wherein the single-stranded guide nucleic acid comprises at least two nucleoside modifications.

### Claim 28 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The ADAR recruiting molecule of any one of claims 2-27, wherein the single-stranded guide nucleic acid comprises at least three nucleoside modifications.

### Claim 29 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The ADAR recruiting molecule of any one of claims 2-28, wherein more than 25% of the nucleosides of the single-stranded guide nucleic acid comprise a nucleoside modification.

### Claim 30 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The ADAR recruiting molecule of any one of claims 2-29, wherein more than 50% of the nucleosides in the single-stranded guide nucleic acid comprise a nucleoside modification.

### Claim 31 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The ADAR recruiting molecule of any one of claims 2-30, wherein more than 75% of the nucleosides in the single-stranded guide nucleic acid comprise a nucleoside modification.

### Claim 32 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The ADAR recruiting molecule of any one of claims 2-31, wherein the single-stranded guide nucleic acid comprises at least one backbone modification.

### Claim 33 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The ADAR recruiting molecule of any one of claims 2-32, wherein the single-stranded guide nucleic acid comprises at least two backbone modifications.

### Claim 34 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The ADAR recruiting molecule of any one of claims 2-33, wherein the single-stranded guide nucleic acid comprises at least three backbone modifications.

### Claim 35 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The ADAR recruiting molecule of any one of claims 2-34, wherein more than 25% of the internucleoside linkages in the single-stranded guide nucleic acid comprise a phosphate modification.

### Claim 36 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The ADAR recruiting molecule of any one of claims 2-35, wherein more than 50% of the internucleoside linkages in the single-stranded guide nucleic acid comprise a phosphate modification.

### Claim 37 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The ADAR recruiting molecule of any one of claims 2-36, wherein more than 75% of the internucleoside linkages in the single-stranded guide nucleic acid comprise a phosphate modification.

### Claim 38 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The ADAR recruiting molecule of any one of claims 2-37, wherein the single-stranded guide nucleic acid comprises sufficient complementarity to hybridize with a target sequence.

### Claim 39 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The ADAR recruiting molecule of any one of claims 2-38, wherein the single-stranded guide nucleic acid comprises three consecutive non-modified nucleotides.

### Claim 40 (depends on 39)

The ADAR recruiting molecule of claim 39, wherein at least one of the three consecutive non-modified nucleotides pairs with a nucleotide adjacent to a target adenosine in the target sequence.

### Claim 41 (depends on 40)

The ADAR recruiting molecule of claim 40, wherein the middle nucleotide of the three consecutive non-modified nucleotides is opposite the target adenosine.

### Claim 42 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The ADAR recruiting molecule of any one of claims 2-41, wherein a nucleotide opposite a target adenosine comprises:
(a) cytosine (C);
(b) a natural or modified nucleotide which does not base pair with adenosine (A); and/or
(c) a natural or modified nucleotide which base pairs with guanine (G) or inosine (I).

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The ADAR recruiting molecule of any one of claims 1-42, wherein each RNA strand of the double-stranded RNA duplex is at least 10 nucleotides in length.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The ADAR recruiting molecule of any one of claims 1-43, wherein each RNA strand of the double-stranded RNA duplex is fewer than or equal to 100 nucleotides in length.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The ADAR recruiting molecule of any one of claims 1-44, wherein each RNA strand of the double-stranded RNA duplex is about 5 to about 80 nucleotides in length.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The ADAR recruiting molecule of any one of claims 1-45, wherein each RNA strand of the double-stranded RNA duplex is about 5 to about 60 nucleotides in length.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The ADAR recruiting molecule of any one of claims 1-46, wherein each RNA strand of the double-stranded RNA duplex is about 5 to about 40 nucleotides in length.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The ADAR recruiting molecule of any one of claims 1-47, wherein each RNA strand of the double-stranded RNA duplex is about 5 to about 30 nucleotides in length.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The ADAR recruiting molecule of any one of claims 1-48, wherein each RNA strand of the double-stranded RNA duplex is about 10 to about 27 nucleotides in length.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The ADAR recruiting molecule of any one of claims 1-49, wherein each RNA strand of the double-stranded RNA duplex is about 15 to about 26 nucleotides in length.

### Claim 51 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The ADAR recruiting molecule of any one of claims 2-50, wherein the single-stranded guide nucleic acid is at least 5 nucleotides in length.

### Claim 52 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The ADAR recruiting molecule of any one of claims 2-51, wherein the single-stranded guide nucleic acid is fewer than or equal to 100 nucleotides in length.

### Claim 53 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The ADAR recruiting molecule of any one of claims 2-52, wherein the single-stranded guide nucleic acid is about 5 to about 80 nucleotides in length.

### Claim 54 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The ADAR recruiting molecule of any one of claims 2-53, wherein the single-stranded guide nucleic acid is about 5 to about 60 nucleotides in length.

### Claim 55 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The ADAR recruiting molecule of any one of claims 2-54, wherein the single-stranded guide nucleic acid is about 5 to about 40 nucleotides in length.

### Claim 56 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The ADAR recruiting molecule of any one of claims 2-55, wherein the single-stranded guide nucleic acid is about 5 to about 30 nucleotides in length.

### Claim 57 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The ADAR recruiting molecule of any one of claims 2-56, wherein the single-stranded guide nucleic acid is about 10 to about 27 nucleotides in length.

### Claim 58 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The ADAR recruiting molecule of any one of claims 2-57, wherein the single-stranded guide nucleic acid is about 15 to about 26 nucleotides in length.

### Claim 59 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The ADAR recruiting molecule of any one of claims 2-58, wherein the single-stranded guide nucleic acid comprises at least 25% complementarity with a target sequence.

### Claim 60 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The ADAR recruiting molecule of any one of claims 2-59, wherein the single-stranded guide nucleic acid comprises at least 50% complementarity with a target sequence.

### Claim 61 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The ADAR recruiting molecule of any one of claims 2-60, wherein the single-stranded guide nucleic acid comprises at least 75% complementarity with a target sequence.

### Claim 62 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The ADAR recruiting molecule of any one of claims 2-61, wherein the single-stranded guide nucleic acid comprises at least 90% complementarity with a target sequence.

### Claim 63 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The ADAR recruiting molecule of any one of claims 2-62, wherein the single-stranded guide nucleic acid comprises at least 95% complementarity with a target sequence.

### Claim 64

An RNA targeting molecule comprising:
(a) a double-stranded RNA duplex, wherein the double-stranded RNA duplex comprises two strands of RNA of an equal number of nucleotides, which two RNA strands are not connected to one another by means of a hairpin, wherein the 5′ nucleotide of each RNA strand is complementary to the 3′ nucleotide of the other RNA strand, wherein the double-stranded RNA duplex comprises at least one base pair mismatch, wherein the mismatch is not positioned at either terminal nucleotide base pair of the double-stranded RNA duplex; and
(b) a single-stranded guide nucleic acid.

### Claim 65 (depends on 64)

The RNA targeting molecule of claim 64, wherein the double-stranded RNA duplex comprises at least one nucleoside modification and/or at least one backbone modification.

### Claim 66 (depends on 64, 65)

The RNA targeting molecule of claim 64 or claim 65, wherein the double-stranded RNA duplex comprises at least one nucleoside modification and at least one backbone modification.

### Claim 67 (depends on 64, 65, 66)

The RNA targeting molecule of any one of claims 64-66, wherein the at least one nucleoside modification comprises a 2′-aminoethyl, a 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid, a 2′-O-methyl, a 2′-O-methoxyethyl (2′O-MOE), or a 2′-fluoro modification.

### Claim 68 (depends on 64, 65, 66, 67)

The RNA targeting molecule of any one of claims 64-67, wherein the at least one backbone modification comprises a phosphorothioate modification.

### Claim 69 (depends on 64, 65, 66, 67, 68)

The RNA targeting molecule of any one of claims 64-68, wherein the at least one backbone modification of the double-stranded RNA duplex is positioned within 1-5 nucleotides of the terminal nucleotide of the RNA strand on which it is located.

### Claim 70 (depends on 64, 65, 66, 67, 68, 69)

The RNA targeting molecule of any one of claims 64-69, wherein the at least one backbone modification of the double-stranded RNA duplex is positioned within 1-3 nucleotides of the terminal nucleotide of the RNA strand on which it is located.

### Claim 71 (depends on 64, 65, 66, 67, 68, 69, 70)

The RNA targeting molecule of any one of claims 64-70, wherein the at least one backbone modification of the double-stranded RNA duplex is positioned within 1 nucleotide of the terminal nucleotide of the RNA strand on which it is located.

### Claim 72 (depends on 64, 65, 66, 67, 68, 69, 70, 71)

The RNA targeting molecule of any one of claims 64-71, wherein the double-stranded RNA duplex comprises more than one nucleoside modification.

### Claim 73 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72)

The RNA targeting molecule of any one of claims 64-72, wherein the double-stranded RNA duplex comprises more than two nucleoside modifications.

### Claim 74 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The RNA targeting molecule of any one of claims 64-73, wherein more than 25% of the nucleosides in the double-stranded RNA duplex comprise a nucleoside modification.

### Claim 75 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The RNA targeting molecule of any one of claims 64-74, wherein more than 50% of the nucleosides in the double-stranded RNA duplex comprise a nucleoside modification.

### Claim 76 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The RNA targeting molecule of any one of claims 64-75, wherein more than 75% of the nucleosides in the double-stranded RNA duplex comprise a nucleoside modification.

### Claim 77 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The RNA targeting molecule of any one of claims 64-76, wherein the double-stranded RNA duplex comprises more than one backbone modification.

### Claim 78 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The RNA targeting molecule of any one of claims 64-77, wherein the double-stranded RNA duplex comprises more than two backbone modifications.

### Claim 79 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The RNA targeting molecule of any one of claims 64-78, wherein the double-stranded RNA duplex comprises more than three backbone modifications.

### Claim 80 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The RNA targeting molecule of any one of claims 64-79, wherein more than 25% of the internucleoside linkages of the double-stranded RNA duplex comprise a modification.

### Claim 81 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The RNA targeting molecule of any one of claims 64-80, wherein more than 50% of the internucleoside linkages of the double-stranded RNA duplex comprise a modification.

### Claim 82 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The RNA targeting molecule of any one of claims 64-81, wherein more than 75% of the internucleoside linkages of the double-stranded RNA duplex comprise a modification.

### Claim 83 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The RNA targeting molecule of any one of claims 64-82, further comprising nucleotides attached to the 3′ end or 5′ end of at least one of the RNA strands of the double-stranded RNA duplex creating a 3′ and/or 5′ end overhang.

### Claim 84 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The RNA targeting molecule of any one of claims 64-83, further comprising an additional moiety.

### Claim 85 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The RNA targeting molecule of any one of claims 64-84, further comprising a linker.

### Claim 86 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The RNA targeting molecule of any one of claims 64-85, wherein the single-stranded guide nucleic acid is guide ribonucleic acid (gRNA).

### Claim 87 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The RNA targeting molecule of any one of claims 64-86, wherein the single-stranded guide nucleic acid comprises at least one nucleoside modification.

### Claim 88 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The RNA targeting molecule of any one of claims 64-87, wherein the single-stranded guide nucleic acid comprises at least one backbone modification.

### Claim 89 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The RNA targeting molecule of any one of claims 64-88, wherein the single-stranded guide nucleic acid comprises at least one nucleoside modification and at least one backbone modification.

### Claim 90 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The RNA targeting molecule of any one of claims 64-89, wherein the single-stranded guide nucleic acid comprises at least two nucleoside modifications.

### Claim 91 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The RNA targeting molecule of any one of claims 64-90, wherein the single-stranded guide nucleic acid comprises at least three nucleoside modifications.

### Claim 92 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The RNA targeting molecule of any one of claims 64-91, more than 25% of the nucleosides of the single-stranded guide nucleic acid comprise a nucleoside modification.

### Claim 93 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The RNA targeting molecule of any one of claims 64-92, wherein more than 50% of the nucleosides in the single-stranded guide nucleic acid comprise a nucleoside modification.

### Claim 94 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The RNA targeting molecule of any one of claims 64-93, wherein more than 75% of the nucleosides in the single-stranded guide nucleic acid comprise a nucleoside modification.

### Claim 95 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The RNA targeting molecule of any one of claims 64-94, wherein the single-stranded guide nucleic acid comprises at least one backbone modification.

### Claim 96 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The RNA targeting molecule of any one of claims 64-95, wherein the single-stranded guide nucleic acid comprises at least two backbone modifications.

### Claim 97 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The RNA targeting molecule of any one of claims 64-96, wherein the single-stranded guide nucleic acid comprises at least three backbone modifications.

### Claim 98 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The RNA targeting molecule of any one of claims 64-97, wherein more than 25% of the internucleoside linkages in the single-stranded guide nucleic acid comprise a phosphate modification.

### Claim 99 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The RNA targeting molecule of any one of claims 64-98, wherein more than 50% of the internucleoside linkages in the single-stranded guide nucleic acid comprise a phosphate modification.

### Claim 100 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The RNA targeting molecule of any one of claims 64-99, wherein more than 75% of the internucleoside linkages in the single-stranded guide nucleic acid comprise a phosphate modification.

### Claim 101 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The RNA targeting molecule of any one of claims 64-100, wherein the single-stranded guide nucleic acid comprises sufficient complementarity to hybridize with a target sequence.

### Claim 102 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The RNA targeting molecule of any one of claims 64-101, wherein the single-stranded guide nucleic acid comprises three consecutive non-modified nucleotides.

### Claim 103 (depends on 102)

The RNA targeting molecule of claim 102, wherein at least one of the three consecutive non-modified nucleotides of the single-stranded guide nucleic acid is complementary to a nucleotide adjacent to a target adenosine in the target sequence.

### Claim 104 (depends on 102, 103)

The RNA targeting molecule of claim 102 or claim 103, wherein the middle nucleotide of the three consecutive non-modified nucleotides is opposite the target adenosine.

### Claim 105 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)

The RNA targeting molecule of any one of claims 64-104, wherein a nucleotide opposite a target adenosine comprises:
(a) cytosine (C);
(b) a natural or modified nucleotide which does not base pair with adenosine (A); and/or
(c) a natural or modified nucleotide which base pairs with guanine (G) or inosine (I).

### Claim 106 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The RNA targeting molecule of any one of claims 64-105, wherein each RNA strand of the double-stranded RNA duplex is at least 5 nucleotides in length.

### Claim 107 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The RNA targeting molecule of any one of claims 64-106, wherein each RNA strand of the double-stranded RNA duplex is fewer than or equal to 100 nucleotides in length.

### Claim 108 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The RNA targeting molecule of any one of claims 64-107, wherein each RNA strand of the double-stranded RNA duplex is about 5 to about 80 nucleotides in length.

### Claim 109 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

The RNA targeting molecule of any one of claims 64-108, wherein each RNA strand of the double-stranded RNA duplex is about 5 to about 60 nucleotides in length.

### Claim 110 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)

The RNA targeting molecule of any one of claims 64-109, wherein each RNA strand of the double-stranded RNA duplex is about 5 to about 40 nucleotides in length.

### Claim 111 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The RNA targeting molecule of any one of claims 64-110, wherein each RNA strand of the double-stranded RNA duplex is about 5 to about 30 nucleotides in length.

### Claim 112 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111)

The RNA targeting molecule of any one of claims 64-111, wherein each RNA strand of the double-stranded RNA duplex is about 10 to about 27 nucleotides in length.

### Claim 113 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112)

The RNA targeting molecule of any one of claims 64-112, wherein each RNA strand of the double-stranded RNA duplex is about 15 to about 26 nucleotides in length.

### Claim 114 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The RNA targeting molecule of any one of claims 64-113, wherein the single-stranded guide nucleic acid is at least 5 nucleotides in length.

### Claim 115 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The RNA targeting molecule of any one of claims 64-114, wherein the single-stranded guide nucleic acid is fewer than or equal to 100 nucleotides in length.

### Claim 116 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The RNA targeting molecule of any one of claims 64-115, wherein the single-stranded guide nucleic acid is about 5 to about 80 nucleotides in length.

### Claim 117 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The RNA targeting molecule of any one of claims 64-116, wherein the single-stranded guide nucleic acid is about 5 to about 60 nucleotides in length.

### Claim 118 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The RNA targeting molecule of any one of claims 64-117, wherein the single-stranded guide nucleic acid is about 5 to about 40 nucleotides in length.

### Claim 119 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The RNA targeting molecule of any one of claims 64-118, wherein the single-stranded guide nucleic acid is about 5 to about 30 nucleotides in length.

### Claim 120 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119)

The RNA targeting molecule of any one of claims 64-119 wherein the single-stranded guide nucleic acid is about 10 to about 27 nucleotides in length.

### Claim 121 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The RNA targeting molecule of any one of claims 64-120, wherein the single-stranded guide nucleic acid is about 15 to about 26 nucleotides in length.

### Claim 122 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The RNA targeting molecule of any one of claims 64-121, wherein the single-stranded guide nucleic acid comprises at least 25% complementarity with a target sequence.

### Claim 123 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

The RNA targeting molecule of any one of claims 64-122, wherein the single-stranded guide nucleic acid comprises at least 50% complementarity with a target sequence.

### Claim 124 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The RNA targeting molecule of any one of claims 64-123, wherein the single-stranded guide nucleic acid comprises at least 75% complementarity with a target sequence.

### Claim 125 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The RNA targeting molecule of any one of claims 64-124, wherein the single-stranded guide nucleic acid comprises at least 90% complementarity with a target sequence.

### Claim 126 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The RNA targeting molecule of any one of claims 64-125, wherein the single-stranded guide nucleic acid comprises at least 95% complementarity with a target sequence.

### Claim 127 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126)

A method of deaminating a target nucleic acid in a subject, comprising, administering an effective amount of the ADAR recruiting molecule of any one of claims 2-63, and/or the RNA targeting molecule of any one of claims 64-126, wherein the ADAR recruiting molecule and/or the RNA targeting molecule comprises a single-stranded guide nucleic acid comprising a sequence which is sufficiently complementary to a target sequence to hybridize with the target sequence.

### Claim 128 (depends on 127)

The method of claim 127, wherein the target sequence comprises a target adenosine.

### Claim 129 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126)

A method of treating a subject, comprising administering the ADAR recruiting molecule of any one of claims 2-63, and/or the RNA targeting molecule of any one of claims 64-126, wherein the ADAR recruiting molecule and/or the RNA targeting molecule comprises a single-stranded guide nucleic acid comprising a sequence which is sufficiently complementary to a target sequence to hybridize with the target sequence.

### Claim 130 (depends on 129)

The method of claim 129, wherein the target sequence comprises a target adenosine.

### Claim 131 (depends on 130)

The method of claim 130, wherein the target adenosine is related to a disease or disorder, wherein the deamination of the target adenosine treats the disease or disorder.

### Claim 132 (depends on 131)

The method of claim 131, wherein the disease or disorder is selected from: Cystic fibrosis, Hurler Syndrome, alpha-1-antitrypsin (A1AT) deficiency, Parkinson's disease, Alzheimer's disease, albinism, Amyotrophic lateral sclerosis, Asthma, beta-thalassemia (β-thalassemia), Cadasil syndrome, Charcot-Marie-Tooth disease, Chronic Obstructive Pulmonary Disease (COPD), Distal Spinal Muscular Atrophy (DSMA), Duchenne/Becker muscular dystrophy, Dystrophic Epidermolysis bullosa, Epidermylosis bullosa, Fabry disease, Factor V Leiden associated disorders, Familial Adenomatous, Polyposis, Galactosemia, Gaucher's Disease, Glucose-6-phosphate dehydrogenase, Haemophilia, Hereditary Hematochromatosis, Hunter Syndrome, Huntington's disease, Inflammatory Bowel Disease (IBD), Inherited polyagglutination syndrome, Leber congenital amaurosis, Lesch-Nyhan syndrome, Lynch syndrome, Marfan syndrome, Mucopolysaccharidosis, Muscular Dystrophy, Myotonic dystrophy types I and II, neurofibromatosis, Niemann-Pick disease type A, B, and C, NY-eso1 related cancer, Peutz-Jeghers Syndrome, Phenylketonuria, Pompe's disease, Primary Ciliary Disease, Prothrombin mutation related disorders, such as the Prothrombin G20210A mutation, Pulmonary Hypertension, Retinitis Pigmentosa, Sandhoff Disease, Severe Combined Immune Deficiency Syndrome (SCID), Sickle Cell Anemia, Spinal Muscular Atrophy, Stargardt's Disease, Tay-Sachs Disease, Usher syndrome, X-linked immunodeficiency, Sturge-Weber Syndrome, and cancer.

### Claim 133

An RNA targeting molecule comprising:
(a) a double-stranded RNA duplex comprising two RNA strands;
(b) a single-stranded guide nucleic acid; and
(c) a linker;
wherein the double-stranded RNA duplex is connected to the single-stranded guide nucleic acid via the linker.

### Claim 134 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to the 5′ terminal nucleotide of one of the two strands of the RNA duplex.

### Claim 135 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to the 3′ terminal nucleotide of one of the two strands of the RNA duplex.

### Claim 136 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to a nucleotide located between the 5′ terminal nucleotide and the 3′ terminal nucleotide of one of the two strands of the RNA duplex.

### Claim 137 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to the 5′ nucleotide of the guide nucleic acid.

### Claim 138 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to the 3′ nucleotide of the guide nucleic acid.

### Claim 139 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to a nucleotide located between the 5′ terminal nucleotide and the 3′ terminal nucleotide of the guide nucleic acid.

### Claim 140 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to a sugar of the 5′ terminal nucleotide, or a 3′ hydroxyl or sugar of the 3′ terminal nucleotide of one strand of the RNA duplex.

### Claim 141 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to a sugar of the 5′ terminal nucleotide, or a 3′ hydroxyl or sugar of the 3′ terminal nucleotide of the guide nucleic acid.

### Claim 142 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to an internucleoside linkage of one RNA strand of the RNA duplex.

### Claim 143 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to an internucleoside linkage of the guide nucleic acid.

### Claim 144 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to a nucleoside sugar of one RNA strand of the RNA duplex.

### Claim 145 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker is connected to a nucleoside sugar of the guide nucleic acid.

### Claim 146 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker connects the 3′ end of the guide nucleic acid to the 5′ end of one RNA strand of the RNA duplex.

### Claim 147 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker connects the 5′ end of the guide nucleic acid to the 3′ end of one RNA strand of the RNA duplex.

### Claim 148 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker connects the 3′ end of the guide nucleic acid to the 3′ end of one RNA strand of the RNA duplex.

### Claim 149 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker connects the 5′ end of the guide nucleic acid to the 5′ end of one RNA strand of the RNA duplex.

### Claim 150 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker connects the 3′ end of the guide nucleic acid to a nucleotide located between the 5′ terminal nucleotide and the 3′ terminal nucleotide of one RNA strand of the RNA duplex.

### Claim 151 (depends on 150)

The RNA targeting molecule of claim 150, wherein the linker is connected to an internucleoside linkage or a nucleoside sugar of one RNA strand of the RNA duplex.

### Claim 152 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker connects the 5′ end of the guide nucleic acid to a nucleotide located between the 5′ terminal nucleotide and the 3′ terminal nucleotide of one RNA strand of the RNA duplex.

### Claim 153 (depends on 152)

The RNA targeting molecule of claim 152, wherein the linker is connected to an internucleoside linkage or a nucleoside sugar of one RNA strand of the RNA duplex.

### Claim 154 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker connects the 3′ end of one RNA strand of the RNA duplex to a nucleotide located between the 5′ terminal nucleotide and the 3′ terminal nucleotide of the guide nucleic acid.

### Claim 155 (depends on 154)

The RNA targeting molecule of claim 154, wherein the linker is connected to an internucleoside linkage or a nucleoside sugar of the guide nucleic acid.

### Claim 156 (depends on 133)

The RNA targeting molecule of claim 133, wherein the linker connects the 5′ end of one RNA strand of the RNA duplex to a nucleotide located between the 5′ terminal nucleotide and the 3′ terminal nucleotide of the guide nucleic acid.

### Claim 157 (depends on 156)

The RNA targeting molecule of claim 156, wherein the linker is connected to an internucleoside linkage or a nucleoside sugar of the guide nucleic acid.

### Claim 158 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the linker is an unbranched linker.

### Claim 159 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the linker is a branched linker.

### Claim 160 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the linker is a non-covalent linker comprising a first binding partner covalently attached to one strand of the double-stranded RNA duplex, and a second binding partner covalently attached to the single-stranded guide nucleic acid, wherein the first and second binding partners form a non-covalent complex connecting the double-stranded RNA duplex to the single-stranded guide nucleic acid.

### Claim 161 (depends on 160)

The RNA targeting molecule of claim 160, wherein the first binding partner is a receptor and the second binding partner is a ligand specific for the receptor.

### Claim 162 (depends on 160)

The RNA targeting molecule of claim 160, wherein the second binding partner is a receptor and the first binding partner is a ligand specific for the receptor.

### Claim 163 (depends on 160)

The RNA targeting molecule of claim 160, wherein the first binding partner is biotin and the second binding partner is streptavidin.

### Claim 164 (depends on 160)

The RNA targeting molecule of claim 160, wherein the first binding partner is streptavidin and the second binding partner is biotin.

### Claim 165 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the linker is a covalent linker.

### Claim 166 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the linker is greater than or equal to 4 atoms in length.

### Claim 167 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the linker is fewer than or equal to 180 atoms in length.

### Claim 168 (depends on 165)

The RNA targeting molecule of claim 165, wherein the linker comprises an alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, repeated ethylene glycol group, ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide linkage, a product of a click reaction, a triazole from an azide-alkyne cycloaddition, carbamate, a cleavable linker, a redox cleavable linker, a reductively cleavable linker, a disulfide group, an acid cleavable linker, a hydrazone group, an ester group, an acetal group, a ketal group, an esterase cleavable linker, an ester group, a phosphatase cleavable linker, a phosphate group, a peptidase cleavable linker, a peptide bond, a bio-cleavable linker, DNA, RNA, disulfide, amide, functionalized monosaccharides, or oligosaccharides of galactosamine.

### Claim 169 (depends on 165)

The RNA targeting molecule of claim 165, wherein the linker comprises a moiety derived from a click chemistry reaction.

### Claim 170 (depends on 169)

The RNA targeting molecule of claim 169, wherein the moiety derived from a click chemistry reaction is a triazole, diazole, diazine, sulfide bond, maleimide ring, succinimide ring, ester, or amide.

### Claim 171 (depends on 165)

The RNA targeting molecule of claim 165, wherein the linker comprises one or more amino acids.

### Claim 172 (depends on 165)

The RNA targeting molecule of claim 165, wherein the linker comprises an organic molecule, group, polymer, or chemical domain.

### Claim 173 (depends on 172)

The RNA targeting molecule of claim 172, wherein the chemical domain comprises an amide, urea, carbamate, carbonate, ester, acetal, ketal, phosphoramidite, hydrazone, imine, oxime, disulfide, silyl, hydrazine, hydrazone, thiol, imidazole, carbon-carbon bond, carbon-heteroatom bond, or azo domain.

### Claim 174 (depends on 165)

The RNA targeting molecule of claim 165, wherein the linker is polymeric.

### Claim 175 (depends on 174)

The RNA targeting molecule of claim 174, wherein the polymeric linker comprises polyethylene, polyethylene glycol, polyamide, polyester, or polyether.

### Claim 176 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the linker comprises any one of Formula (I)-Formula (VII).

### Claim 177 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the double-stranded RNA duplex comprises:
(a) an RNA strand comprising a sequence with at least 70% identity to Strand Ref.: 24 or 27; and
(b) an RNA strand comprising a sequence with at least 70% identity to Strand Ref.: 25 or 28;
and wherein the single-stranded guide nucleic acid comprises a sequence with at least 70% identity to Strand Ref.: 23 or 26.

### Claim 178 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the double-stranded RNA duplex comprises:
(a) an RNA strand comprising a sequence according to Strand Ref.: 24 or 27; and
(b) an RNA strand comprising a sequence according to Strand Ref.: 25 or 28;
and wherein, the at least one single-stranded guide nucleic acid comprises a sequence according to Strand Ref.: 23 or 26.

### Claim 179 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The RNA targeting molecule of any one of claims 133-176, wherein the double-stranded RNA duplex comprises:
(a) an RNA strand comprising a sequence with at least 70% identity to Strand Ref.: 353 or 355; and
(b) an RNA strand comprising a sequence with at least 70% identity to Strand Ref.: 815 or 818.

### Claim 180 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The RNA targeting molecule of any one of claims 133-176, wherein the double-stranded RNA duplex comprises:
(a) an RNA strand comprising a sequence according to Strand Ref.: 353 or 355; and
(b) an RNA strand comprising a sequence according to Strand Ref.: 815 or 818.

### Claim 181 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The RNA targeting molecule of any one of claims 133-176, wherein the double-stranded RNA duplex comprises:
(a) an RNA strand comprising a sequence with at least 70% identity to Strand Ref.: 641 or 643; and
(b) an RNA strand comprising a sequence with at least 70% identity to Strand Ref.: 841 or 869.

### Claim 182 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The RNA targeting molecule of any one of claims 133-176, wherein the double-stranded RNA duplex comprises:
(a) an RNA strand comprising a sequence according to Strand Ref.: 641 or 643; and
(b) an RNA strand comprising a sequence according to Strand Ref.: 841 or 869.

### Claim 183 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, comprising two or more double-stranded RNA duplexes.

### Claim 184 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claims, comprising two or more single-stranded guide nucleic acids.

### Claim 185 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, comprising 2-10 double-stranded RNA duplexes.

### Claim 186 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claims, comprising 2-10 single-stranded guide nucleic acids.

### Claim 187 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, comprising 2-5 double-stranded RNA duplexes.

### Claim 188 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claims, comprising 2-5 single-stranded guide nucleic acids.

### Claim 189 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188)

The RNA targeting molecule of any one of claims 133-188, wherein one strand of the double-stranded RNA duplex is not covalently connected to the other strand of the RNA duplex.

### Claim 190 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The RNA targeting molecule of any one of claims 133-189, wherein the double-stranded RNA duplex does not comprise a hairpin connecting one strand of the RNA duplex to the other strand of the RNA duplex.

### Claim 191 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190)

The RNA targeting molecule of any one of claims 133-190, wherein the double-stranded RNA duplex comprises two RNA strands having an equal number of nucleotides.

### Claim 192 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191)

The RNA targeting molecule of any one of claims 133-191, wherein the double-stranded RNA duplex comprises two RNA strands having a different number of nucleotides.

### Claim 193 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192)

The RNA targeting molecule of any one of claims 133-192, wherein the linker does not comprise a nucleotide or nucleoside.

### Claim 194 (depends on 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193)

The RNA targeting molecule of any one of claims 133-193, wherein the linker is a non-nucleic acid linker.

### Claim 195

An RNA targeting molecule comprising:
(a) a first double-stranded RNA duplex comprising two RNA strands;
(b) a second double-stranded RNA duplex comprising two RNA strands;
(b) a single-stranded guide nucleic acid; and
(c) a linker;
wherein the first double-stranded RNA duplex is connected to the second double-stranded RNA duplex via the linker.

### Claim 196

An RNA targeting molecule comprising:
(a) a double-stranded RNA duplex comprising two RNA strands;
(b) a first single-stranded guide nucleic acid;
(c) a second single-stranded guide nucleic acid; and
(c) a linker;
wherein the first single-stranded guide nucleic acid is connected to the second single-stranded guide nucleic acid via the linker.

### Claim 197 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the double-stranded RNA duplex comprises at least one mismatch.

### Claim 198 (depends on 133)

The RNA targeting molecule of claim 133, or any other prior claim, wherein the single-stranded guide nucleic acid comprises at least two mismatches relative to a target sequence.
